Plaque Psoriasis

SAN DIEGO — Patients treated with JNJ-2113 for moderate to severe plaque psoriasis maintained skin clearance up to 1 year, according to a late-breaking presentation at the 2024 American Academy of Dermatology Annual Meeting.

Arcutis has entered into a licensing agreement with Sato Pharmaceutical Co. Ltd. to develop, manufacture and commercialize topical roflumilast in Japan for the treatment of multiple skin conditions, according to a company press release.

The efficacy of tapinarof cream 1% has validated the aryl hydrocarbon receptor as a therapeutic target for the treatment of atopic dermatitis, according to a study.

Using the efficiency frontier approach to negotiate prices for plaque psoriasis biologics may lead to substantial price reductions that better align with clinical benefits in the U.S., according to a study.

In this video, Ahmad Shatil Amin, MD, medical practice director at the Northwestern Medicine Dermatology, discusses the most reliable diagnostic criteria for psoriasis.

In this video, Ahmad Shatil Amin, MD, medical practice director at the Northwestern Medicine Dermatology, discusses the challenges of maintaining long-term remission of psoriasis.

In this video, Ahmad Shatil Amin, MD, medical practice director at the Northwestern Medicine Dermatology, discusses what needs to be taken into account when choosing between topical and systemic treatment for patients with psoriasis.

In this video, Ahmad Shatil Amin, MD, medical practice director at the Northwestern Medicine Dermatology, discusses what clinicians should consider in their awareness of psoriasis.

In this video, Ahmad Shatil Amin, MD, medical practice director at the Northwestern Medicine Dermatology, discusses the latest treatment options for psoriasis.

Patients with plaque psoriasis that have lower baseline blood monocyte counts may respond to secukinumab therapy earlier than patients with higher counts, according to a study.